Tudorache et al., 2017
10.1007/s00403-013-1332-y [DOI] [PubMed] [Google Scholar] 56.Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, et al
You can read the full article at Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial In a phase 3 trial conducted in Japan, the efficacy and safety of tirzepatide, a new medication for type 2 diabetes, were compared to dulaglutide
Hydrogen Sulfide
Initially, this drug was marketed towards individuals with T2DM [90] but is now being used as an anti-obesity drug
Her decision came as WeightWatchers shifted from its classic community-based model to a more comprehensive approach that blends proven prescriptions with long-term lifestyle support